The USRDS: what you need to know about what it can and can't tell us about ESRD.

This article summarizes the administrative structure underlying the Unites States Renal Data System (USRDS); summarizes incidence, prevalence, patient characteristics, and treatment modalities; and describes data regarding clinical indicators and preventive care, hospitalization, survival, and costs. The USRDS recently instituted a comprehensive assessment system to characterize the transition to the new Centers for Medicare & Medicaid Services Prospective Payment System, which bundles into a single payment several integral components of dialysis care. This challenging initiative will be an important component of future USRDS Annual Data Reports. The main strengths of the USRDS are its size and representativeness, nearly complete inclusion of the US end-stage renal disease population, and linkage to Medicare claims. Limitations include lack of continuous validation of its methods, lack of complete comorbidity and laboratory data at registration, an initial survival bias, and lack of accuracy of cause-of-death reporting.

[1]  M. Landray,et al.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[2]  Winfried März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005 .

[3]  R. Foley,et al.  Long interdialytic interval and mortality among patients receiving hemodialysis. , 2011, The New England journal of medicine.

[4]  J. Coresh,et al.  Prevalence of chronic kidney disease in the United States. , 2007, JAMA.

[5]  W. Suki,et al.  Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. , 2007, Kidney international.

[6]  R. Foley,et al.  Atherosclerotic Renovascular Disease in Older US Patients Starting Dialysis, 1996 to 2001 , 2006, Circulation.

[7]  G. Moneta Atherosclerotic Renovascular Disease in Older US Patients Starting Dialysis, 1996 to 2001 , 2008 .

[8]  M. Rocco,et al.  Comparison of causes of death using HEMO Study and HCFA end-stage renal disease death notification classification systems. The National Institutes of Health-funded Hemodialysis. Health Care Financing Administration. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  E. Rackow Rehospitalizations among patients in the Medicare fee-for-service program. , 2009, The New England journal of medicine.

[10]  Gert Mayer,et al.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.